• Moberg Derma AB, of Stockholm, Sweden, said the German-Federal Institute for Drugs and Medical Devices granted approval for a Phase I trial of Limtop, a product in development for actinic keratosis, genital warts and basal cell carcinoma. The drug is a new formulation of an immunomodulatory compound that has shown improved delivery to skin tissue in preclinical studies.